This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Nov 18;402(10415):1833-1834.

doi: 10.1016/S0140-6736(23)01619-7.

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis

Shivali Devjani¹, Priya V Engel², Sogol S Javadi³, Brandon Smith⁴, Jashin J Wu⁵

Affiliations

Affiliations

¹ SUNY Downstate College of Medicine, New York, NY, USA.
² California University of Science and Medicine, Colton, CA, USA.
³ David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
⁴ Drexel University College of Medicine, Drexel University, Philadelphia, PA, USA.
⁵ Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: jashinwu@gmail.com.

PMID: 37980089
DOI: 10.1016/S0140-6736(23)01619-7

Comment

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis

Shivali Devjani et al. Lancet. 2023.

. 2023 Nov 18;402(10415):1833-1834.

doi: 10.1016/S0140-6736(23)01619-7.

Authors

Shivali Devjani¹, Priya V Engel², Sogol S Javadi³, Brandon Smith⁴, Jashin J Wu⁵

Affiliations

¹ SUNY Downstate College of Medicine, New York, NY, USA.
² California University of Science and Medicine, Colton, CA, USA.
³ David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
⁴ Drexel University College of Medicine, Drexel University, Philadelphia, PA, USA.
⁵ Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: jashinwu@gmail.com.

PMID: 37980089
DOI: 10.1016/S0140-6736(23)01619-7

No abstract available

PubMed Disclaimer

Comment in

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Guttman-Yassky E, et al. Lancet. 2023 Nov 18;402(10415):1834. doi: 10.1016/S0140-6736(23)01618-5. Lancet. 2023. PMID: 37980090 No abstract available.

Comment on

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Guttman-Yassky E, et al. Lancet. 2023 Jan 21;401(10372):204-214. doi: 10.1016/S0140-6736(22)02037-2. Epub 2022 Dec 9. Lancet. 2023. PMID: 36509097 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science